The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy-Reference-Cited by-同舟云学术

The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy

Published:2016-06-03 Issue:3 Volume:100 Page:212-214
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Villaruz LC¹,Socinski MA¹

Affiliation:

1. University of Pittsburgh Cancer Institute; Pittsburgh Pennsylvania USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference6 articles.

1. Nivolumab vs. Docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

2. Nivolumab vs. Docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2015

4. Late breaking abstract: Atezolizumab monotherapy vs docetaxel in 2L/3L non-small lung cancer: primary analyses for efficacy, safety, and predictive biomarkers from a randomized phase II study. (POPLAR);Vansteenkiste;Lancet,2016

5. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC);Rizvi;J. Clin. Oncol.,2015

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review;Journal of Cancer Metastasis and Treatment;2024-05-28

2. Identifying a 6-Gene Prognostic Signature for Lung Adenocarcinoma Based on Copy Number Variation and Gene Expression Data;Oxidative Medicine and Cellular Longevity;2022-09-28

3. Gracillin Shows Potential Efficacy Against Non-Small Cell Lung Cancer Through Inhibiting the mTOR Pathway;Frontiers in Oncology;2022-03-22

4. Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis;Molecular Diagnosis & Therapy;2022-02-01

5. Relationship between the absolute lymphocyte count/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma;Annals of Palliative Medicine;2021-10